Primary HIV-1 drug resistance in the C-terminal domains of viral reverse transcriptase among drug-naïve patients from Southern Brazil

Journal of Clinical Virology

Volumn 52, Issue 4, 2011, Pages 373-376

  Santos, André F ^a   Silveira, Jussara ^b   Muniz, Cláudia P ^a   Tornatore, Michele ^b   Góes, Lívia R ^a   Mendoza Sassi, Raul A ^b   Martinez, Ana M B ^b   Tupinambás, Unaí ^c   Greco, Dirceu B ^c   Soares, Marcelo A ^a,d  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE   (Brazil)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^d INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Brazil; C terminal; Connection; Drug resistance mutation; Primary resistance; RNase H

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; VIRUS RNA;

ADULT; ARTICLE; BRAZIL; CODON; FEMALE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL;

ADULT; BRAZIL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; POLYMERASE CHAIN REACTION; PREVALENCE; RNA, VIRAL; SEQUENCE ANALYSIS, DNA;

EID: 82755182588     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.09.005     Document Type: Article

References (35)

1. Robertson D.L., Anderson J.P., Bradac J.A., Carr J.K., Foley B., Funkhouser R.K., et al. HIV-1 nomenclature proposal. Science 2000, 288(5463):55-56.
2. Vidal N., Bazepeo S.E., Mulanga C., Delaporte E., Peeters M. Genetic characterization of eight full-length HIV type 1 genomes from the Democratic Republic of Congo (DRC) reveal a new subsubtype A5, in the A radiation that predominates in the recombinant structure of CRF26_A5U. AIDS Res Hum Retroviruses 2009, 25(8):823-832.
3. de Silva T.I., Turner R., Hué S., Trikha R., van Tienen C., Onyango C., et al. HIV-1 subtype distribution in the Gambia and the significant presence of CRF49_cpx, a novel circulating recombinant form. Retrovirology 2010, 7:82.
4. Santos A.F., Soares M.A. HIV genetic diversity and drug resistance. Viruses 2010, 2:503-531.
5. Hemelaar J., Gouws E., Ghys P.D., Osmanov S. WHO-UNAIDS network for HIV isolation and characterisation global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011, 25(5):679-689.
6. Johnson V.A., Brun-Vézinet F., Clotet B., Günthard H.F., Kuritzkes D.R., Pillay D., et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010, 18(5):156-163.
7. Nikolenko G.N., Palmer S., Maldarelli F., Mellors J.W., Coffin J.M., Pathak V.K. Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. Proc Natl Acad Sci USA 2005, 102(6):2093-2098.
8. Nikolenko G.N., Delviks-Frankenberry K.A., Palmer S., Maldarelli F., Fivash M.J., Coffin J.M., et al. Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance. Proc Natl Acad Sci USA 2007, 104(1):317-322.
9. Yap S.H., Sheen C.W., Fahey J., Zanin M., Tyssen D., Lima V.D., et al. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med 2007, 4:e335.
10. Hachiya A., Kodama E.N., Sarafianos S.G., Schuckmann M.M., Sakagami Y., Matsuoka M., et al. Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J Virol 2008, 82(7):3261-3270.
11. Gupta S., Fransen S., Paxinos E.E., Stawiski E., Huang W., Petropoulos C.J. Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance. Antimicrob Agents Chemother 2010, 54(5):1973-1980.
12. Lengruber B., Delviks-Frankenberry K.A., Nikolenko G.N., Baumannb J., Santos A.F., Pathak V.K., et al. Phenotypic characterization of drug-associated mutations in HIV-1 RT connection and RNase H domains and their correlation with TAMs. J Antimicrob Chemother 2011, 66(4):702-708.
13. Hachiya A., Shimane K., Sarafianos S.G., Kodama E.N., Sakagami Y., Negishi F., et al. Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naïve patients. Antiviral Res 2009, 82:115-121.
14. Delviks-Frankenberry K.A., Nikolenko G.N., Maldarelli F., Hase S., Takebe Y., Pathak V.K. Subtype-specific differences in the human immunodeficiency virus type 1 reverse transcriptase connection subdomain of CRF01_AE are associated with higher levels of resistance to 3'-azido-3'-deoxythymidine. J Virol 2009, 82(3):8502-8513.
15. Brehm J.H., Koontz D., Meteer J.D., Pathak V., Sluis-Cremer N., Mellors J.W. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine. J Virol 2007, 81(15):7852-7859.
16. Ehteshami M., Beilhartz G.L., Scarth B.J., Tchesnokov E.P., McCormick S., Wynhoven B., et al. Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3'-azido-3'-deoxythymidine through both RNase H-dependent and -independent mechanisms. J Biol Chem 2008, 283(32):22222-22232.
17. Tanuma J., Hachiya A., Ishigaki K., Gatanaga H., Minh Lien T.T., Hien N.D., et al. Impact of CRF01_AE-specific polymorphic mutations G335D and A371V in the connection subdomain of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on susceptibility to nucleoside RT inhibitors. Microbes Infect 2010, 12(14-15):1170-1177.
18. von Wyl V., Ehteshami M., Demeter L.M., Bürgisser P., Nijhuis M., Symons J., et al. Swiss HIV Cohort Study. HIV-1 reverse transcriptase connection domain mutations: dynamics of emergence and implications for success of combination antiretroviral therapy. Clin Infect Dis 2010, 51(5):620-628.
19. Dau B., Ayers D., Singer J., Harrigan P.R., Brown S., Kyriakides T., et al. Connection domain mutations in treatment-experienced patients in the OPTIMA trial. J Acquir Immune Defic Syndr 2010, 54(2):160-166.
20. Soares E.A., Makamche M.F., Siqueira J.D., Lumngwena E., Mbuagbaw J., Kaptue L., et al. Molecular diversity and polymerase gene genotypes of HIV-1 among treatment-naïve Cameroonian subjects with advanced disease. J Clin Virol 2010, 48(3):173-179.
21. Santos A.F., Schrago C.G., Martinez A.M., Mendoza-Sassi R., Silveira J., Sousa T.M., et al. Epidemiologic and evolutionary trends of HIV-1 CRF31_BC-related strains in Southern Brazil. J Acquir Immune Defic Syndr 2007, 45(3):328-333.
22. Santos A.F., Lengruber R.B., Soares E.A., Jere A., Sprinz E., Martinez A.M., et al. Conservation patterns of HIV-1 RT connection and RNase H domains: identification of new mutations in NRTI-treated patients. PLoS ONE 2008, 3(3):e1781.
23. Hall T.A. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser 1999, 41:95-98.
24. Tamura K., Dudley J., Nei M., Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007, 24(8):1596-1599.
25. Rhee S.Y., Gonzales M.J., Kantor R., Betts B.J., Ravela J., Shafer R.W. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 2003, 31(1):298-303.
26. Ross L., Lim M.L., Liao Q., Wine B., Rodriguez A.E., Weinberg W., et al. Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naïve HIV-infected individuals from 40 United States cities. HIV Clin Trials 2007, 8(1):1-8.
27. Youmans E., Tripathi A., Albrecht H., Gibson J.J., Duffus W.A. Transmitted antiretroviral drug resistance in individuals with newly diagnosed HIV infection: South Carolina 2005-2009. South Med J 2011, 104(2):95-101.
28. Chilton D.N., Castro H., Lattimore S., Harrison L.J., Fearnhill E., Delpech V., et al. HIV type-1 drug resistance in antiretroviral treatment-naïve adults infected with non-B subtype virus in the United Kingdom. Antivir Ther 2010, 15(7):985-991.
29. Bonura F., Tramuto F., Vitale F., Perna A.M., Viviano E., Romano N. Group for HIV-1 Antiretroviral Studies in Sicily. Transmission of drug-resistant HIV type 1 strains in HAART-naïve patients: a 5-year retrospective study in Sicily, Italy. AIDS Res Hum Retroviruses 2010, 26(9):961-965.
30. Bartmeyer B., Kuecherer C., Houareau C., Werning J., Keeren K., Somogyi S., et al. Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter Cohort. PLoS ONE 2010, 5(10):e12718.
31. Palma A.C., Araújo F., Duque V., Borges F., Paixão M.T., Camacho R. Portuguese SPREAD Network. Molecular epidemiology and prevalence of drug resistance-associated mutations in newly diagnosed HIV-1 patients in Portugal. Infect Genet Evol 2007, 7(3):391-398.
32. Inocencio L.A., Pereira A.A., Sucupira M.C., Fernandez J.C., Jorge C.P., Souza D.F., et al. Brazilian network for HIV drug resistance surveillance: a survey of individuals recently diagnosed with HIV. J Int AIDS Soc 2009, 12(1):20.
33. Sprinz E., Netto E.M., Patelli M., Lima J.S., Furtado J.J., da Eira M., et al. Primary antiretroviral drug resistance among HIV type 1-infected individuals in Brazil. AIDS Res Hum Retroviruses 2009, 25(9):861-867.
34. Van Houtte M., Picchio G., Van Der Borght K., Pattery T., Lecocq P., Bacheler L.T. A comparison of HIV-1 drug susceptibility as provided by conventional phenotyping and by a phenotype prediction tool based on viral genotype. J Med Virol 2009, 81(10):1702-1709.
35. Delviks-Frankenberry K.A., Lengruber R.B., Santos A.F., Soares M.A., Kearney M., Maldarelli F., et al. Enhanced NRTI and NNRTI resistance is associated with mutations in the HIV-1 reverse transcriptase connection subdomain of subtype C patients. Antivir Ther 2010, 15(Suppl. 2):A78.